Article
Icotinib versus chemotherapy as adjuvant treatment for stage II-IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial.
The Lancet. Respiratory medicine - 1 Sept 2021
He Jianxing, Su Chunxia, Liang Wenhua, Xu Shidong, Wu Lin, Fu Xiangning, Zhang Xiaodong, Ge Di, Chen Qun, Mao Weimin, Xu Lin, Chen Chun, Hu Bing, Shao Guoguang, Hu Jian, Zhao Jian, Liu Xiaoqing, Liu Zhidong, Wang Zheng, Xiao Zemin, Gong Taiqian, Lin Wen, Li Xingya, Ye Feng, Liu Yang, Ma Haitao, Huang Yunchao, Zhou Jianying, Wang Zhonglin, Fu Junke, Ding Lieming, Mao Li, Zhou Caicun
Abstract excerpt
BACKGROUND: Icotinib has provided survival benefits for patients with advanced, epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC). We aimed to compare icotinib with chemotherapy in patients with EGFR-mutant stage II-IIIA NSCLC after complete tumour resection. Here, we report the results from the preplanned interim analysis of the study. METHODS: In this multicentre, randomised,...
Topics
Join the communities discussing this publication.